Bevacizumab vs. Ranibizumab in preserving or improving vision in patients with wet, age-related macular degeneration: A cost-effectiveness review

Clinical Medicine Insights: Therapeutics

Volumn 4, Issue , 2012, Pages 29-38

  Nwanze, Chukwuemeka C ^a,b   Akinwale, Abumere ^c   Adelman, Ron A ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c JOSLIN DIABETES CENTER   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Avastin; Bevacizumab; Cost effectiveness; Lucentis; Quality adjusted life years (QALY); Ranibizumab

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

AGE DISTRIBUTION; AGED; CLINICAL PROTOCOL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SENSITIVITY ANALYSIS; UNSPECIFIED SIDE EFFECT; VISION; VISUAL ACUITY;

EID: 84857829013     PISSN: 1179559X     EISSN: 1179559X     Source Type: Journal    
DOI: 10.4137/CMT.S7439     Document Type: Review

References (38)

1. Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfo- veal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment-TAP and VIP report No. 2. Archives of Ophthalmology. 2003;121:1253-68.
2. Bressler NM. Photodynamic therapy of subfoveal choroidal neovasculariza- tion in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Archives of Ophthalmology. 2001;119:198-207.
3. Photodynamic therapy of subfoveal choroidal neovascularization in age- related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Archives of Ophthalmology. 1999;117:1329-45.
4. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. The New England Journal of Medicine. 2004;351:2805-16.
5. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age- related macular degeneration. The New England Journal of Medicine. 2006;355:1419-31.
6. Klaver CC, Assink JJ, van Leeuwen R, et al. Incidence and progression rates of age-related maculopathy: the Rotterdam Study. Investigative Ophthalmology and Visual Science. 2001;42:2237-41.
7. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Archives of Ophthalmology. 2004;122:477-85.
8. Bressler NM. Age-related macular degeneration is the leading cause of blind- ness. The Journal of the American Medical Association. 2004;291:1900-1.
9. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Archives of Ophthalmology. 2004;122:564-72.
10. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impair- ment in the year 2002. Bulletin of the World Health Organization. 2004;82: 844-51.
11. Augood C, Fletcher A, Bentham G, et al. Methods for a population-based study of the prevalence of and risk factors for age-related maculopathy and macular degeneration in elderly European populations: the EUREYE study. Ophthalmic Epidemiology. 2004;11:117-29.
12. Klein R, Chou CF, Klein BE, Zhang X, Meuer SM, Saaddine JB. Prevalence of age-related macular degeneration in the US population. Archives of Ophthalmology. 2011;129:75-80.
13. Smiddy WE. Economic implications of current age-related macular degen- eration treatments. Ophthalmology. 2009;116:481-7.
14. Day S, Acquah K, Lee PP, Mruthyunjaya P, Sloan FA. Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007. American Journal of Ophthalmology. 2011.
15. Hurley SF, Matthews JP, Guymer RH. Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. Cost effectiveness and resource allocation: C/E 2008;6:12.
16. Brown MM, Brown GC, Brown HC, Peet J. A value-based medicine analy- sis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology. 2008;115:1039-45. e5.
17. Fletcher EC, Lade RJ, Adewoyin T, Chong NV. Computerized model of cost-utility analysis for treatment of age-related macular degeneration. Ophthalmology. 2008;115:2192-8.
18. Services CfMM. National Healthcare Expenditure Data. In: Centers for 2011.
19. Rosenthal MB. Hard choices-alternatives for reining in Medicare and Medicaid spending. The New England Journal of Medicine. 2011;364: 1887-90.
20. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. The New England Journal of Medicine. 2011;364:1897-908.
21. Raftery JP, Lotery A. The cheaper drug, bevacizumab, should be referred to NICE. BMJ. 2007;334:381-2.
22. Patel JJ, Mendes MA, Bounthavong M, Christopher ML, Boggie D, Morreale AP. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model. Journal of Evaluation in Clinical Practice. 2010.
23. Rosenfeld PJ. Bevacizumab versus ranibizumab for AMD. The New England Journal of Medicine. 2011;364:1966-7.
24. Carneiro AM, Costa R, Falcao MS, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmologica. 2011.
25. Qian J, Lu Q, Tao Y, Jiang YR. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy. Retina. 2011;31:161-8.
26. Lim LS, Cheung CM, Mitchell P, Wong TY. Emerging evidence concerning systemic safety of anti-VEGF agents-should ophthalmologists be concerned? American Journal of Ophthalmology. 2011;152:329-1.
27. Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age- related macular degeneration. Lancet. 2007;370:204-6.
28. Minino AM, Xu J, Kochanek KD, Tejada-Vera B. Death in the United States, 2007. NCHS Data Brief. 2009:1-8.
29. Brown GC, Sharma S, Brown MM, Kistler J. Utility values and age-related macular degeneration. Archives of Ophthalmology. 2000;118:47-51.
30. Brown MM, Brown GC, Sharma S, Landy J. Health care economic analyses and value-based medicine. Survey of Ophthalmology. 2003;48:204-3.
31. Brown MM, Brown GC, Stein JD, Roth Z, Campanella J, Beauchamp GR. Age-related macular degeneration: economic burden and value-based medi- cine analysis. Canadian Journal of Ophthalmology Journal Canadien D'ophtalmologie. 2005;40:277-87.
32. Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology. 2011;118:523-30.
33. Agency for Healthcare Research and Quality. HCUP Databases. Healthcare Cost and Utilization Project (HCUP). In. Rockville, MD; 2011.
34. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Medical Care. 2008;46:349-56.
35. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Medical decision making: An International Journal of the Society for Medical Decision Making. 2000;20:332-42.
36. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Review of Pharmacoeconomics and Outcomes Research. 2008;8:165-78.
37. Administration USFaD. FDA Alerts Health Care Professionals of Infection Risk from Repackaged Avastin Intravitreal Injections. In: Administration USFaD, ed; 2011.
38. Edney A. VA Drops Roche's Avastin for Eye Disease on Infection. Bloombergcom September 22, 2011.